Switch theme
Sign up to access all valuation multiples
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
2006
2.1K+
Last FY Revenue $211M
Last FY EBITDA $86.4M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Anthem Biosciences achieved revenue of $211M and an EBITDA of $86.4M.
Anthem Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anthem Biosciences valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $211M | XXX | XXX | XXX |
| Gross Profit | XXX | $126M | XXX | XXX | XXX |
| Gross Margin | XXX | 60% | XXX | XXX | XXX |
| EBITDA | XXX | $86.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 41% | XXX | XXX | XXX |
| EBIT | XXX | $67.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | 32% | XXX | XXX | XXX |
| Net Profit | XXX | $51.6M | XXX | XXX | XXX |
| Net Margin | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Anthem Biosciences's stock price is INR 825 (or $9).
Anthem Biosciences has current market cap of INR 463B (or $5.3B), and EV of INR 457B (or $5.2B).
See Anthem Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $5.3B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Anthem Biosciences has market cap of $5.3B and EV of $5.2B.
Anthem Biosciences's trades at 26.3x EV/Revenue multiple, and 64.4x EV/EBITDA.
Equity research analysts estimate Anthem Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anthem Biosciences's P/E ratio is not available.
See valuation multiples for Anthem Biosciences and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 26.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 64.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 83.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 107.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1187.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnthem Biosciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $28K for the same period.
Anthem Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anthem Biosciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anthem Biosciences and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anthem Biosciences acquired XXX companies to date.
Last acquisition by Anthem Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Anthem Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Anthem Biosciences founded? | Anthem Biosciences was founded in 2006. |
| Where is Anthem Biosciences headquartered? | Anthem Biosciences is headquartered in India. |
| How many employees does Anthem Biosciences have? | As of today, Anthem Biosciences has 2.1K+ employees. |
| Is Anthem Biosciences publicy listed? | Yes, Anthem Biosciences is a public company listed on NSE. |
| What is the stock symbol of Anthem Biosciences? | Anthem Biosciences trades under ANTHEM ticker. |
| When did Anthem Biosciences go public? | Anthem Biosciences went public in 2025. |
| Who are competitors of Anthem Biosciences? | Similar companies to Anthem Biosciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Anthem Biosciences? | Anthem Biosciences's current market cap is $5.3B |
| Is Anthem Biosciences profitable? | Yes, Anthem Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
